Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.

Abstract:

INTRODUCTION:Silodosin is a new uroselective alpha-blocker with high pharmacological selectivity for the (1A) adrenoceptor. It is an effective and well-tolerated treatment in men with lower urinary tract symptoms (LUTS), due to presumed bladder outlet obstruction secondary to benign prostatic hyperplasia (BPH). The efficacy of silodosin is at least equivalent to existing selective alpha-1 antagonists such as tamsulosin. A beneficial consequence of its high selectivity is improved cardiovascular safety and failure to interact with other therapies such as anti-hypertensives and phosphodiesterase type-5 inhibitors. AREAS COVERED:This paper discusses the mechanism of action, uroselectivity and clinical efficacy/tolerability of Silodosin. Additionally, drug interactions and urodynamic effects are reviewed with a focus on ejaculatory dysfunction. EXPERT OPINION:Silodosin is a rapidly efficacious and safe agent in the treatment of LUTS/BPH in men. A lack of clinically important cardiovascular side effects makes it of potential use in the elderly. There is a higher risk of ejaculatory dysfunction, which may lead to discontinuation in younger men. The availability of generic counterparts may make this compound less marketable in countries with social healthcare systems.

authors

Osman NI,Chapple CR,Cruz F,Desgrandchamps F,Llorente C,Montorsi F

doi

10.1517/14656566.2012.714368

subject

Has Abstract

pub_date

2012-10-01 00:00:00

pages

2085-96

issue

14

eissn

1465-6566

issn

1744-7666

journal_volume

13

pub_type

杂志文章,评审
  • The changing pattern of adherence to antiretroviral therapy assessed at two time points, 12 months apart, in a cohort of HIV-infected children.

    abstract:OBJECTIVE:In a previous multicentre study including 129 HIV-infected children, non-adherence to antiretroviral therapy was detected in 16% of patients and was mainly related to psychosocial rather than clinical or demographic features. The aim of this study was to explore the evolving pattern of adherence and its deter...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究

    doi:10.1517/14656560903376178

    authors: Giannattasio A,Albano F,Giacomet V,Guarino A

    更新日期:2009-12-01 00:00:00

  • Therapeutic options for Acinetobacter baumannii infections.

    abstract::Acinetobacter baumannii is an important cause of nosocomial infections, mainly in patients in intensive care units. This microorganism, although with slight differences depending on the country, presents resistance to multiple antimicrobial agents, occasionally including resistance to colistin: hence, it can be consid...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.4.587

    authors: Vila J,Pachón J

    更新日期:2008-03-01 00:00:00

  • Advances in pharmacotherapy for hyperphosphatemia in renal disease.

    abstract:INTRODUCTION:Hyperphosphatemia in chronic kidney disease (CKD) is considered as an independent risk factor for surrogate clinical end points like vascular calcification (VC) and bone disease, or hard clinical outcomes like cardiovascular events. Various treatment options are available for phosphate removal or reduction...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1092521

    authors: Spasovski G

    更新日期:2015-01-01 00:00:00

  • Use of single-pill combination therapy in the evolving paradigm of hypertension management.

    abstract::The use of antihypertensive therapy is an evolving paradigm. Although blood pressure (BP) control rates remain low, there have been improvements that may be attributable in part to a recent shift in clinical guidelines that recognizes that most patients will require multiple drugs to reach BP goals and encourages clin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656560902980210

    authors: Calhoun DA

    更新日期:2009-08-01 00:00:00

  • Intramuscular Midazolam for treatment of Status Epilepticus.

    abstract:INTRODUCTION:Status epilepticus (SE) is a common neurological and medical emergency. It has high mortality and morbidity rates, which typically correlate with seizure semiology and duration; therefore, prompt and proper pharmacological intervention is paramount. In a pre-hospital setting, establishing venous access can...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1810236

    authors: Riva A,Iapadre G,Grasso EA,Balagura G,Striano P,Verrotti A

    更新日期:2021-01-01 00:00:00

  • Clopidogrel in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention.

    abstract::Clopidogrel has become a mainstay in the management of acute coronary syndrome patients over the past decade, as well as an essential component of percutaneous coronary intervention (PCI) pharmacotherapy. Until recently, no prospective study has evaluated the effectiveness of clopidogrel in the setting of an ST-segmen...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.12.1669

    authors: Hamdalla H,Moliterno DJ

    更新日期:2006-08-01 00:00:00

  • Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke.

    abstract::The administration of oral aspirin within 48 h and tissue plasminogen activator within 3 h of ischaemic stroke onset remain the only treatments that have been shown to have clinical benefit. There has been much excitement about neuroprotection over the last two decades, as it may minimise the harmful effects of ischae...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.12.1571

    authors: Ly JV,Zavala JA,Donnan GA

    更新日期:2006-08-01 00:00:00

  • Abatacept: a novel treatment for rheumatoid arthritis.

    abstract::Rheumatoid arthritis (RA) is a chronic, autoimmune disease that has traditionally been treated with non-biologic and biologic disease-modifying antirheumatic drugs (DMARDs). Although these agents have become firmly established as effective RA treatments, some patients do not have an adequate response. The recent appro...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.14.2371

    authors: Lundquist LM

    更新日期:2007-10-01 00:00:00

  • The therapeutic management of differentiated thyroid cancer.

    abstract:BACKGROUND:The management of thyroid cancer is difficult because the tumors comprise a wide range of biologic behaviors, from small papillary thyroid microcarcinomas that pose little or no threat to survival for the patient, to anaplastic thyroid cancers that are arguably the most lethal tumor. Although it may be diffi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.15.2627

    authors: Sipos JA,Mazzaferri EL

    更新日期:2008-10-01 00:00:00

  • Novel therapy for childhood acute lymphoblastic leukemia.

    abstract:INTRODUCTION:During recent decades, the prognosis of childhood acute lymphoblastic leukemia (ALL) has improved dramatically, nowadays, reaching a cure rate of almost 90%. These results are due to a better management and combination of old therapies, refined risk-group stratification and emergence of minimal residual di...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1340938

    authors: Santiago R,Vairy S,Sinnett D,Krajinovic M,Bittencourt H

    更新日期:2017-08-01 00:00:00

  • Chemotherapeutic inhibitors in the treatment of prostate cancer.

    abstract:INTRODUCTION:Prostate cancer being the second leading cause of death in men in Western countries remains a major challenge in healthcare. Several novel agents targeting signaling pathways in prostate cancer have recently been approved by the US Food and Drug Administration (FDA) but there is still an unmet need for new...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.852184

    authors: Deshmukh RR,Schmitt SM,Hwang C,Dou QP

    更新日期:2014-01-01 00:00:00

  • Emerging pharmacotherapeutic agents for insomnia: a hypnotic panacea?

    abstract::The burden of insomnia has had a significant effect not only on the socioeconomic matrix, but also the medical terrain, as signified by the increased morbidity and mortality of its associated psychiatric and organic sequelae. To this end, a plethora of pharmacotherapeutic agents have been recently introduced that addr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.13.1731

    authors: Navab P,Guilleminault C

    更新日期:2006-09-01 00:00:00

  • Apomorphine therapy in Parkinson's disease: a review.

    abstract::Motor fluctuations are common and distressing for patients with advanced Parkinson's disease. Subcutaneous apomorphine injections can be an extremely valuable adjunctive therapy. In this review, the authors discuss the history, pharmacology, efficacy, safety and proper administration of apomorphine for treating 'off' ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.16.2799

    authors: Haq IU,Lewitt PA,Fernandez HH

    更新日期:2007-11-01 00:00:00

  • Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?

    abstract:INTRODUCTION:Historically, there were few effective and durable treatments for metastatic melanoma. Recently, mutation based targeted therapies have revolutionized treatment and outcomes for patients with metastatic melanoma. Specifically, inhibitors aimed at BRAF, NRAS, and C-KIT mutations are now commonly used in tre...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1299710

    authors: Turner MC,Rossfeld K,Salama AK,Tyler D,Beasley G

    更新日期:2017-04-01 00:00:00

  • Quality improvement in the management of people with epilepsy and intellectual disability: the development of clinical guidance.

    abstract::Introduction: This clinical guidance looks at the specific concerns of delivery of medical treatment for people with epilepsy and intellectual disability (ID). People with ID have not been included in licensing drug trials of AEDs. However, this population has an over-representation of seizure comorbidity, treatment r...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1695780

    authors: Watkins L,O'Dwyer M,Kerr M,Scheepers M,Courtenay K,Shankar R

    更新日期:2020-02-01 00:00:00

  • Lacosamide in patients with pharmacoresistant epilepsy.

    abstract:INTRODUCTION:Lacosamide is a novel antiepileptic drug licensed in the US and Europe as adjunctive therapy for partial-onset seizures in adults. The efficacy, safety, tolerability and favorable pharmacokinetic profile in the adult population suggest that lacosamide could be of benefit for patients with partial-onset sei...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.713347

    authors: Verrotti A,Loiacono G,Olivieri C,Zulli E,Zaccara G

    更新日期:2012-10-01 00:00:00

  • Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.

    abstract:INTRODUCTION:Many patients with type 2 diabetes mellitus (T2DM) fail to achieve the desired A1c goal because the antidiabetic medications used do not correct the underlying pathophysiologic abnormalities and monotherapy is not sufficiently potent to reduce the A1c to the 6.5 - 7.0% range. Insulin resistance and islet (...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1114098

    authors: Triplitt C,Solis-Herrera C,Cersosimo E,Abdul-Ghani M,Defronzo RA

    更新日期:2015-01-01 00:00:00

  • Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder.

    abstract::The International Continence Society has defined overactive bladder (OAB) as urinary urgency, with or without urge urinary incontinence, usually with urinary frequency and nocturia. Approximately 17% of men and women in the US report OAB symptoms, which can affect quality of life. Trospium chloride, which has recently...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.8.1409

    authors: Zinner NR

    更新日期:2005-07-01 00:00:00

  • Advances in orally administered pharmacotherapy for the treatment of migraine.

    abstract:INTRODUCTION:Migraine is a common and highly disabling neurological disorder whose acute treatment remains problematic and unsatisfactory in a high percentage of cases. Consequently, there remains a need for new symptomatic therapies that can be easily handled by patients (i.e. by oral administration). AREAS COVERED:T...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1549223

    authors: Martelletti P,Giamberardino MA

    更新日期:2019-02-01 00:00:00

  • Duodenal levodopa infusion for the treatment of Parkinson's disease.

    abstract::Motor fluctuations are a common problem in the long-term management of Parkinson's disease (PD), resulting in disability and impaired quality of life. The relatively short serum half-life (approximately 90 min) of oral levodopa/carbidopa and its erratic absorption due to delayed and inconsistent gastric emptying (a no...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.5.657

    authors: Samanta J,Hauser RA

    更新日期:2007-04-01 00:00:00

  • Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia.

    abstract:INTRODUCTION:Treating acute myeloid leukemia (AML) in older adults remains daunting. The unique biology often renders conventional chemotherapies less effective. Accurately predicting the toxicities of treatment is another unresolved challenge. Treatment planning thus requires a good knowledge of the current trial data...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1465562

    authors: Michaelis LC,Klepin HD,Walter RB

    更新日期:2018-06-01 00:00:00

  • Safinamide in the treatment of Parkinson's disease.

    abstract:IMPORTANCE OF THE FIELD:Current therapy for Parkinson's disease (PD) is primarily directed at reversing the motor symptoms that are the consequence of dopamine deficiency and includes levodopa, dopamine agonists and monoamine oxidase (MAO) B inhibitors. New drugs offering both dopaminergic and non-dopaminergic actions ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.511612

    authors: Schapira AH

    更新日期:2010-09-01 00:00:00

  • Clinical review of Clostridium difficile infection: an update on treatment and prevention.

    abstract:INTRODUCTION:Clostridium difficile infection (CDI) has become a significant healthcare-associated infection and is strongly associated with antibiotic use. Practice guidelines have recently been revised incorporating updated recommendations for diagnosis, treatment, and prevention. AREAS COVERED:This review discusses ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1524872

    authors: Daniels LM,Kufel WD

    更新日期:2018-11-01 00:00:00

  • Treating epileptic emergencies - pharmacological advances.

    abstract:INTRODUCTION:Epileptic emergencies are frequently encountered and include ictal events as status epilepticus or seizure clusters, and non-ictal situations like postictal psychosis or acute drug side effects. The aim of this review was to describe recent pharmacological advances in the treatment of epileptic emergencies...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2016.1241236

    authors: Zelano J,Ben-Menachem E

    更新日期:2016-11-01 00:00:00

  • Update on pharmacotherapy of myoclonic seizures.

    abstract:INTRODUCTION:Myoclonic seizures are brief, involuntary muscular jerks arising from the central nervous system that can occur in different epilepsy syndromes, including idiopathic generalized epilepsies or the most severe group of epileptic encephalopathies. Valproate is commonly the first choice alone or in combination...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1280459

    authors: Striano P,Belcastro V

    更新日期:2017-02-01 00:00:00

  • Current and Emerging Pharmacotherapy for Chronic Spontaneous Urticaria: A Focus on Non-biological Therapeutics.

    abstract:INTRODUCTION:Chronic spontaneous urticaria (CSU) refers to urticaria (wheals) or angioedema, which occur for a period of six weeks or longer without an apparent cause. The condition may impair the patient's quality of life. AREAS COVERED:Treatment for CSU is mainly symptomatic. Both AAAAI/ACAAI practice parameters and...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1829593

    authors: Hon KL,Li JTS,Leung AKC,Lee V

    更新日期:2020-09-29 00:00:00

  • Review of the use of topotecan in ovarian carcinoma.

    abstract::Ovarian cancer is the fifth leading cause of cancer deaths in women. The majority of patients present with advanced disease and relapse after first-line platinum-based chemotherapy; therefore, many proceed to treatment with salvage chemotherapy. Currently available treatment options are generally no longer curative in...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.11.2333

    authors: Ahmad T,Gore M

    更新日期:2004-11-01 00:00:00

  • Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.

    abstract:INTRODUCTION:Venous thromboembolism (VTE) causes substantial morbidity and mortality worldwide. The traditional treatment of VTE, with an initial therapy with (low molecular weight) heparin or fondaparinux and a continued treatment with vitamin K antagonists, is effective but has limitations. AREAS COVERED:The current...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.999043

    authors: Vanassche T,Vandenbriele C,Peerlinck K,Verhamme P

    更新日期:2015-04-01 00:00:00

  • Phosphate binder usage in kidney failure patients.

    abstract::Phosphorus binders are used in patients with kidney failure because of the incomplete removal of phosphorus with dialysis and the inability to exclude phosphorus from the diet. Aluminium was the initial phosphorus binder used, but was replaced by calcium-containing binders because of the development of aluminium toxic...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.6.941

    authors: Bleyer AJ

    更新日期:2003-06-01 00:00:00

  • Ezetimibe plus simvastatin for the treatment of hypercholesterolemia.

    abstract:INTRODUCTION:Cardiovascular disease is a major cause of death, and hypercholesterolemia is a major risk factor. Statins, with simvastatin among the most widely used, have ample evidence demonstrating prevention of cardiovascular events and mortality. Ezetimibe is effective at improving serum lipids in combination with ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1041504

    authors: Gryn SE,Hegele RA

    更新日期:2015-06-01 00:00:00